Researchers analyzing data from the ASPREE Trial found that low-dose aspirin was linked to a much lower rate of dementia in a specific group of older adults, but only when their genetic profile was taken into account. The study, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, drew on genetic data from more than 13,500 participants and focused on genes associated with platelet count.
Platelets are small blood components that help form clots. The team assigned each participant a genetic score tied to platelet levels, then compared dementia rates between people taking aspirin and those given a placebo. Among participants in the highest 20 percent of those scores, 1 percent of aspirin users developed dementia, compared with 3.3 percent of placebo recipients. The researchers put that difference at roughly a 70 percent lower relative risk.
The same group carried a clear downside. Major bleeding occurred in 4.4 percent of aspirin users compared with 2.1 percent of placebo recipients, which the authors treated as a significant safety concern.
Lead author Dr. Peter Fransquet of Monash's School of Public Health and Preventive Medicine said the results hint that genetics could someday help identify who might benefit from preventive treatment instead of applying one approach to everyone. Notably, the signal did not involve the well-established genetic risk factors usually linked to Alzheimer's disease and other dementias, which points researchers toward platelet biology as an area worth studying further.
The researchers were clear that these findings are not yet a basis for medical recommendations. The next steps are to see whether the association holds in other populations and then to test it in a clinical trial designed for people with this genetic profile.